SYN X makes progress with CHF (congestive heart failure) and Alzheimer's tests
This article was originally published in Clinica
SYN X Pharma has received an allowance for US patent for a 15-minute, point-of-care test for congestive heart failure (CHF). The test, claimed the firm, is the first to combine, in a single test, two known methods for diagnosing the disease - a marker for myocardial cell injury and a marker for left ventricular overload. Together these indicators for dying cells and heart enlargement provide more accurate patient prognosis, said Toronto, Canada based SYN X.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.